MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Sponsor: ImmunoGen
Participating sites:
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- OLV Aalst, Aalst
- UZ Antwerpen, Antwerpen
- AZ Sint Lucas, Gent
- AZ Klina, Roeselare
